Payment overview · 2025
General Payments
$1,393.75
52 reported records · 14 companies
Healthcare provider profile · identity verified
Siobhan Kuhar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ALBANY, NY · NPI 1881691053
Verified facts
What the public records show
CMS Open Payments records show Siobhan Kuhar, MD received $1,393.75 in general payments during 2025 across 52 reported records.
JAZZ PHARMACEUTICALS INC. accounted for 27.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Hizentra, Sunosi.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sunosi as an associated drug or biological on 19758 records involving 6305 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Sunosi by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Hizentra as an associated drug or biological on 13634 records involving 4691 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Hizentra by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $386.32 | 27.7% | 9 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $207.23 | 14.9% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $190.24 | 13.7% | 14 | 2025 |
| AERIN MEDICAL INC. | Unresolved — no canonical attribution shown | $149.12 | 10.7% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $100.01 | 7.2% | 5 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $91.76 | 6.6% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $73.77 | 5.3% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $51.80 | 3.7% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $43.70 | 3.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.96 | 1.6% | 2 | 2025 |
| Neurent Medical Limited | Unresolved — no canonical attribution shown | $20.69 | 1.5% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $20.58 | 1.5% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $20.57 | 1.5% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $15.00 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,242.76 | 50 |
| Education | $150.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $386.32 | 9 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $207.23 | 5 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $190.24 | 14 | 2025 |
Source payment records
|
|||||
| RHINAER STYLUS Normalized: rhinaer stylus |
Device | AERIN MEDICAL INC. | $149.12 | 1 | 2025 |
Source payment records
|
|||||
| VIVAER STYLUS Normalized: vivaer stylus |
Device | AERIN MEDICAL INC. | $149.12 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $143.56 | 6 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $86.25 | 4 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $73.77 | 4 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $43.70 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.96 | 2 | 2025 |
Source payment records
|
|||||
| NEUROMARK Radiofrequency Console Normalized: neuromark radiofrequency console |
Device | Neurent Medical Limited | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| NEUROMARK System Normalized: neuromark system |
Device | Neurent Medical Limited | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Hizentra hizentra |
2025 | Hizentra | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Sunosi sunosi |
2025 | Sunosi | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Sunosi open payments reported associated product |
CMS Open Payments — General Payments 19758 supporting records · 6305 recipient NPIs · example record 1235293059 |
Sunosi · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Hizentra open payments reported associated product |
CMS Open Payments — General Payments 13634 supporting records · 4691 recipient NPIs · example record 1232339012 |
Hizentra · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Famotidine | Famotidine | 244 | 87 |
| Montelukast Sodium | Montelukast Sodium | 214 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 184 | 94 |
| Azelastine Hcl | Azelastine Hcl | 112 | 51 |
| Omeprazole | Omeprazole | 93 | 33 |
| Armodafinil | Armodafinil | 81 | 21 |
| Ipratropium Bromide | Ipratropium Bromide | 73 | 29 |
| Budesonide | Budesonide | 70 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 62 | 23 |
| Trazodone Hcl | Trazodone Hcl | 55 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 15 |
| Sunosi | Solriamfetol Hcl | 38 | suppressed |
| Mupirocin | Mupirocin | 37 | 24 |
| Alprazolam | Alprazolam | 34 | 11 |
| Betamethasone Valerate | Betamethasone Valerate | 33 | 22 |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 33 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 27 |
| Prednisone | Prednisone | 29 | 22 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 20 |
| Ofloxacin | Ofloxacin | 23 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 23 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Gabapentin | Gabapentin | 19 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 18 | 13 |
| Mometasone Furoate | Mometasone Furoate | 18 | 12 |
| Epinephrine | Epinephrine | 17 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Horizant | Gabapentin Enacarbil | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,393.75 · 52 records | JAZZ PHARMACEUTICALS INC. | Andembry, DUPIXENT, Hizentra, INSPIRE, NEFFY, NEUROMARK Radiofrequency Console, NEUROMARK System, NUCALA, RHINAER STYLUS, Sunosi, VIVAER STYLUS, VOQUEZNA, WAKIX, XYWAV, Xembify, Xhance | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Hizentra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Axsome Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error